| A menin-MLL inhibitor induces specific chromatin changes and eradicates disease in models of MLL-rearranged leukemia AV Krivtsov, K Evans, JY Gadrey, BK Eschle, C Hatton, HJ Uckelmann, ... Cancer cell 36 (6), 660-673. e11, 2019 | 272 | 2019 |
| OBI-3424, a novel AKR1C3-activated prodrug, exhibits potent efficacy against preclinical models of T-ALL K Evans, JX Duan, T Pritchard, CD Jones, L McDermott, Z Gu, CE Toscan, ... Clinical Cancer Research 25 (14), 4493-4503, 2019 | 34 | 2019 |
| A combination of sorafenib and nilotinib reduces the growth of castrate-resistant prostate cancer M Archibald, T Pritchard, H Nehoff, RJ Rosengren, K Greish, S Taurin International journal of nanomedicine, 179-201, 2016 | 28 | 2016 |
| Effective targeting of NAMPT in patient-derived xenograft models of high-risk pediatric acute lymphoblastic leukemia K Somers, K Evans, L Cheung, M Karsa, T Pritchard, A Kosciolek, ... Leukemia 34 (6), 1524-1539, 2020 | 24 | 2020 |
| Raloxifene nanomicelles reduce the growth of castrate-resistant prostate cancer T Pritchard, RJ Rosengren, K Greish, S Taurin Journal of Drug Targeting 24 (5), 441-449, 2016 | 20 | 2016 |
| Raloxifene nano-micelles effect on triple-negative breast cancer is mediated through estrogen receptor-β and epidermal growth factor receptor K Greish, H Nehoff, F Bahman, T Pritchard, S Taurin Journal of Drug Targeting 27 (8), 903-916, 2019 | 14 | 2019 |
| A single mouse trial platform for evaluation of novel agents in acute lymphoblastic leukemia by the Pediatric Preclinical Testing Consortium RB Lock, K Evans, T Pritchard, C Toscan, C Mayoh, B Teicher, ... Blood 132, 4010, 2018 | 2 | 2018 |
| Pediatric Preclinical Testing Consortium evaluation of the menin inhibitor, VTP-50469, against xenograft models of MLL-rearranged infant acute lymphoblastic leukemia RB Lock, K Evans, T Pritchard, SW Erickson, Y Guo, DA Claremon, ... Cancer Research 78 (13_Supplement), 3187-3187, 2018 | 1 | 2018 |
| Abstract LB-B16: The AKR1C3-Activated Prodrug OBI-3424 Exerts Profound In Vivo Efficacy Against Preclinical Models of T-Cell Acute Lymphoblastic Leukemia (T … RB Lock, K Evans, R Yung, T Pritchard, BA Teicher, JX Duan, Y Guo, ... Molecular Cancer Therapeutics 17 (1_Supplement), LB-B16-LB-B16, 2018 | 1 | 2018 |
| Abstract LB-B14: Pediatric Preclinical Testing Consortium evaluation of the second-generation selective inhibitor of nuclear export (SINE) compound KPT-8602 K Krytska, K Evans, T Pritchard, M Tsang, R Yung, YP Mosse, ... Molecular Cancer Therapeutics 17 (1_Supplement), LB-B14-LB-B14, 2018 | | 2018 |
| Pediatric Preclinical Testing Consortium evaluation of the second-generation selective inhibitor of nuclear export (SINE) compound KPT-8602 K Krytska, K Evans, T Pritchard, M Tsang, R Yung, YP Mosse, ... MOLECULAR CANCER THERAPEUTICS 17 (1), 2018 | | 2018 |
| The AKR1C3-Activated Prodrug OBI-3424 Exerts Profound In Vivo Efficacy Against Preclinical Models of T-Cell Acute Lymphoblastic Leukemia (T-ALL); a Pediatric Preclinical … RB Lock, K Evans, R Yung, T Pritchard, BA Teicher, JX Duan, Y Guo, ... MOLECULAR CANCER THERAPEUTICS 17 (1), 2018 | | 2018 |
| The nicotinamide phosphoribosyltransferase (NAMPT) inhibitor, OT-82, exhibits in vitro and in vivo efficacy against patient-derived xenograft models of high-risk … K Evans, T Pritchard, MJ Henderson, K Somers, M Karsa, L Cheung, ... Cancer Research 77 (13_Supplement), 1942-1942, 2017 | | 2017 |
| SMA-raloxifene for the management of castrate-resistant prostate cancer TC Pritchard University of Otago, 2015 | | 2015 |
| Effective targeting of NAMPT in patient-derived xenograft models of high-risk pediatric acute lymphoblastic leukemia Running title: NAMPT inhibition in high-risk pediatric ALL K Somers, K Evans, L Cheung, M Karsa, T Pritchard, A Kosciolek, ... | | |
| Micellar Raloxifene improves its pharmacokinetics and cellular uptake with enhanced activity for the treatment of castrate-resistant Prostate cancer T Pritchard, R Rosengren, S Taurin, K Greish | | |
